News Analysis

Lupin – Profit disappoint, but margins look up

Dhuraivel Gunasekaran | Updated on May 15, 2019 Published on May 15, 2019

Tax provisions hurt the bottomline

 

Pharma major Lupin disappointed on the bottomline number, though its margins have started to look up.

It has reported a consolidated net profit of Rs 289.6 crore in the fourth quarter of 2018-19, as against the net loss of Rs 783.5 crore seen in the same quarter in FY-18.

However, the consolidated net profit before exceptional item declined 20 per cent year-on-year (Y-o-Y) during the quarter, mainly due to the higher taxes. The loss in the fourth quarter of the previous fiscal was mainly attributable to an impairment provision of Rs. 1,464.4 crore that the company made on certain intangible assets acquired as a part of Gavis group acquisition.

The tax expenses for the company during the quarter was Rs 300 crore, as against the tax gain of Rs 163 crore seen in the same quarter in the FY-18.

The consolidated total revenue grew 9 per cent YoY in the quarter to Rs 4,326 crore.

Persisting regulatory overhang in US

Lupin’s sales in North America grew by 16 per cent year-on-year (Y-o-Y) in the March quarter to Rs 1,741 crore due to higher contribution from FTF (first-to-file) generic drug Ranexa, ramp-up in Solosec speciality drug and new launches. Over the last few years, Lupin’s US business have been impacted by the price erosion due to competition in key products and regulatory tightening.

However, the company’s US business is expected to get better in the near term due to higher sales in the Ranexa drug and the meaningful generic launches, including Levothyroxine and ProAir.

Lupin is one of the pharma majors to be hit by the regulatory overdrive in the past few years. The recent USFDA inspection at its Mandideep (Unit I) facility, conducted in December 2018, has now been classified as OAI (Official Action Indicated), which increases the risk of receiving a warning letter. The company has indicated that this will not impact the revenue generated from the facility. The resolution for the other two facilities – Goa and Indore (Unit II) that are under the scanner of the USFDA currently have also been delayed. A timely resolution is key to the revenue growth of the company going ahead.

Earlier this month, State Attorney Generals from several US states filed a lawsuit against 19 companies including Lupin on alleged violation of Federal and State Antitrust laws. The States have claimed that they have been hurt because of paying supra-competitive prices for the products they purchased or reimbursed. Any negative outcome will impact the US business of the company.

Traction in other markets

The formulation business in India that accounts for 24 per cent of Lupin’s global sales increased by 9 per cent Y-o-Y in the fourth quarter to Rs 1,053 crore, helped by higher volume in the existing products. However, year-end inventory clearance has impacted the growth numbers. Given its domestic portfolio, which is skewed towards the high-margin chronic segment, the overall revenue of the company is well supported. Under chronic therapies, the company focuses on respiratory, cardiology, diabetes and anti-infectives that have high growth potential.

Operating profit for the quarter stood at Rs 959 crore. Operating margins came in at 22.2 per cent, up 70 bps from the same quarter last year due to due to better product mix and Ranexa’s contribution in the US.

Published on May 15, 2019

A letter from the Editor


Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!

Support Quality Journalism
This article is closed for comments.
Please Email the Editor
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.